Last reviewed · How we verify

NCT05784077: PROSERPin-AF

PRevalence of Obstructive Sleep apnoEa and Reduction of Promoters in AF

Status unknown Last updated 24 March 2023
What this trial tests

trial testing Polysomnography in Atrial Fibrillation in 343 participants. Status unknown.

Timeline
1 January 2020
Primary endpoint
31 December 2022
31 January 2025

Quick facts

Lead sponsorIstituto Auxologico Italiano
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment343
Start date1 January 2020
Primary completion31 December 2022
Estimated completion31 January 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Istituto Auxologico Italiano — full company profile →

Who can join

Adults 18 to 75, any sex, with Atrial Fibrillation or Osa Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to identify how many patients who have atrial fibrillation, also have sleep apnoea. This is important because sleep apnoea can be a trigger to atrial fibrillation and it can be corrected with a simple intervention. Therefore it is important to understand its prevalence (how many patients with atrial fibrillation are affected by it). Also, obesity and sleep disorders are often associated, therefore the evolution of atrial fibrillation is studied in patients who also have obesity and have lost weight compared with patients who did not loose any weight or are not obese. As medications or therapy are not changed, this is an observational study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Polysomnography

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Istituto Auxologico Italiano trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05784077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing